Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 3: Drugs indirectly influencing the dopaminergic system (a review)

By Kadieva M.   Oganesyan É.   Mutsueva S.  

Pharmaceutical Chemistry Journal, Vol. 39, Iss. 11, 2005-11 ,pp. : 565-573

Springer Publishing Company

Access to resources Recommend Favorite

Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 2: dopamine receptors and their agonists

By Kadieva M.   Oganesyan É.   Mutsueva S.  

Pharmaceutical Chemistry Journal, Vol. 39, Iss. 10, 2005-10 ,pp. : 520-532

Springer Publishing Company

Access to resources Recommend Favorite

Motor complications, levodopa metabolism and progression of Parkinson's disease

By Müüller Thomas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 7, 2011-07 ,pp. : 847-855

Informa Healthcare

Access to resources Recommend Favorite

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson's Disease: Meta-Analysis of Randomized Controlled Trials

By Kulisevsky Jaime   Pagonabarraga Javier  

Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. : 147-161

Adis International

Access to resources Recommend Favorite

The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson's Disease

By  

Current Clinical Pharmacology, Vol. 2, Iss. 3, 2007-01 ,pp. : 234-243

Bentham Science Publishers

Access to resources Recommend Favorite